Table 2.
Baseline characteristics and bivariate analysis of participants by BMI status at their first clinic visit (BMI-1) categorized as underweight, normal, and overweight/obesity (N = 531).
| Characteristics | BMI at the first clinic visit (BMI-1) | |||||
|---|---|---|---|---|---|---|
| Total | Underweight | Normal BMI | ††Overweight/obesity | UOR | P-value | |
| Age-1 at ART initiation [in years, (mean ± SD)] | 41.4 ± 8.8 | 40.9 + 10.5 | 41.2 ± 8.6 | 42.2 ± 8.1 | — | 0.520 |
| Gender | ||||||
| Male, n (%) | 163 (30.7) | 45 (56.3) | 99 (29.4) | 19 (16.7) | 1† | — |
| Female, n (%) | 368 (69.3) | 35 (43.7) | 238 (70.6) | 95 (83.3) | 2.64 | 0.001∗ |
| CD4+ cells/mm3at first the clinic visit | ||||||
| Median (IQR) | 132 (47–132) | 99 (41–190) | 133 (44–193) | 150 (69–216) | 0.030∗ | |
| CD4+ cells/mm3 categories at the first clinic visit | ||||||
| ≥350, n (%) | 23 (4.3) | 2 (2.5) | 11 (3.6) | 9 (7.9) | 1† | — |
| Nadir (0–200), n (%) | 408 (76.8) | 62 (77.5) | 266 (78.9) | 80 (70.2) | 0.24 | <0.001∗ |
| 201–349, n (%) | 100 (18.8) | 16 (20.0) | 59 (17.5) | 25 (21.9) | 0.33 | <0.001∗ |
BMI = body mass index; overweight/obesity = aggregate of overweight, obesity and morbidly-obese; UOR = unadjusted odds ratio; ART = antiretroviral therapy; SD = standard deviation; IQR = interquartile rage; ∗p < 0.05; ††outcome of interest; †reference group.